Butyrate, generated by gut microbiota, and its therapeutic role in metabolic syndrome.

@article{Bridgeman2020ButyrateGB,
  title={Butyrate, generated by gut microbiota, and its therapeutic role in metabolic syndrome.},
  author={Stephanie Bridgeman and Wendy Northrop and Phillip E. Melton and Gaewyn Ellison and Philip Newsholme and Cyril Desire Sylvain Mamotte},
  journal={Pharmacological research},
  year={2020},
  pages={
          105174
        }
}
Role of Butyrate, a Gut Microbiota Derived Metabolite, in Cardiovascular Diseases: A comprehensive narrative review
TLDR
Although butyrate exhibits a wide variety of biological activities in different pathways including energy homeostasis, glucose and lipid metabolism, inflammation, oxidative stress, neural signaling, and epigenetic modulation in experimental settings, it remains unclear whether these findings are clinically relevant and whether the molecular pathways are activated bybutyrate in humans.
Effect of Advanced Glycation End-Products and Excessive Calorie Intake on Diet-Induced Chronic Low-Grade Inflammation Biomarkers in Murine Models
TLDR
This review provides a summary of research into biomarkers of diet-induced CLGI in murine models, with a focus on AGEs and obesogenic diets, and presents the physiological effects described in the literature.
Prospects for clinical applications of butyrate-producing bacteria
TLDR
Modulating gut microbiota with dietary approaches may improve intestinal dysbiosis commonly seen in patients with obesity-associated metabolic disorders and to help control obesity and metabolic syndrome.
Resveratrol Butyrate Esters Inhibit Obesity Caused by Perinatal Exposure to Bisphenol A in Female Offspring Rats
TLDR
RBE can suppress BPA-induced obesity in female offspring rats, and it demonstrates excellent modulatory activity on intestinal microbiota, with potential applications in perinatological research.
A Meta-Analysis of Microbial Therapy Against Metabolic Syndrome: Evidence From Randomized Controlled Trials
TLDR
In patients with MetS, the conditioning with microbial therapy notably improves FBG, TC, TG, HDL-C, LDL, WC, BMI, HOMA-IR, and DBP (except for the Study using Bifidobacteriumlactis), however, with no effect in SBP and in HbA1c%.
Connecting the dots: Targeting the microbiome in drug toxicity
TLDR
How the gut microbiota modulates drug toxicity by highlighting the microbiome, microbial enzymes or metabolites, drug metabolites, and host toxicological responses is focused on to facilitate the discovery of microbial targets and mechanisms associated with drug toxicity.
Akt: A Potential Drug Target for Metabolic Syndrome
TLDR
Based on a large number of studies on Akt-related pathways and reactions, it is believed that Akt can be used as a potential drug target to effectively treat metabolic syndrome.
The HDAC Inhibitor Butyrate Impairs β Cell Function and Activates the Disallowed Gene Hexokinase I
TLDR
Although protective effects ofHDAC inhibition have been observed in vivo, potent HDAC inhibition impairs β cell function in vitro, and the chronic low dose and acute high dose butyrate treatments may be more reflective of in vivo effects.
Classification of the Occurrence of Dyslipidemia Based on Gut Bacteria Related to Barley Intake
Barley is a grain rich in β-glucan, a soluble dietary fiber, and its consumption can help maintain good health and reduce the risk of metabolic disorders, such as dyslipidemia. However, the effect of
...
1
2
...

References

SHOWING 1-10 OF 119 REFERENCES
Role of Gut Microbiota-Generated Short-Chain Fatty Acids in Metabolic and Cardiovascular Health
TLDR
The role for gut microbiota-generated SCFA in protecting against the effects of energy dense diets offers an intriguing new avenue for regulating metabolic health and CVD risk.
Gut microbiome and metabolic syndrome.
Gut microbiota and metabolic syndrome.
TLDR
Manipulation of gut microbiota through the administration of prebiotics or probiotics could reduce intestinal low grade inflammation and improve gut barrier integrity, thus, ameliorating metabolic balance and promoting weight loss.
Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects
TLDR
Oral butyrate treatment beneficially affects glucose metabolism in lean but not metabolic syndrome subjects, presumably due to an altered SCFA handling in insulin‐resistant subjects.
Butyrate Regulates Liver Mitochondrial Function, Efficiency, and Dynamics in Insulin-Resistant Obese Mice
TLDR
Hepatic mitochondria were identified as the main target of the beneficial effect of both butyrate-based compounds in reverting insulin resistance and fat accumulation in diet-induced obese mice, and the shift of the mitochondrial dynamic toward fusion bybutyrate and FBA resulted in the improvement of mitochondrial cell energy metabolism but also of glucose homeostasis.
Is butyrate the link between diet, intestinal microbiota and obesity‐related metabolic diseases?
TLDR
It is suggested that butyrate might have an anti‐inflammatory potential that can alleviate obesity‐related metabolic complications, possibly due to its ability to enhance the intestinal barrier function.
Butyrate alleviates metabolic impairments and protects pancreatic β cell function in pregnant mice with obesity.
TLDR
Butyrate shows an obvious function of anti-obesity, and can alleviate the metabolic stress, maintain the β-cell function and protect them from inflammatory response in pregnant obese mouse without obvious fetus toxicity.
Butyrate reduces high-fat diet-induced metabolic alterations, hepatic steatosis and pancreatic beta cell and intestinal barrier dysfunctions in prediabetic mice
TLDR
Results showed that diet supplementation with butyrate inhibits the deleterious effects of high-fat diet intake on metabolic parameters and structure/function of several tissues/organs associated with type 2 diabetes mellitus in a mouse model, suggesting a potential use of this short-chain fatty acid in the treatment of this endocrine-metabolic disorder.
...
1
2
3
4
5
...